Current medicinal chemistry · 2025
Assessment of the Toxicity of Free and PLGA-Encapsulated Phospholipase A2 CB: An In Vitro Approach.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Goncalves Vanessa Barbosa Pinheiro, de Moura Gabriel Acácio, Rodrigues Joao Pedro Viana, Latorre Javier Martinez, Candela-Nogueira Vicente, Soriano-Teruel Paula M, García Fernández Alba, Manez Ramon Martinez, de Medeiros Chaves Marlos, do O Pessoa Claudia, de Lima Anderson Maciel, Soares Andreimar Martins, Nicolete Roberto
Аннотация
BACKGROUND: The use of bioactive molecules isolated from rattlesnake venom and other poisons has been ongoing for years. Among these bioactive compounds present in snake venom, crotoxin (CTX) stands out as a β-heterodimeric neurotoxin isolated from the venom of Crotalus durissus terrificus. Research on this toxin for its applicability to tumor inhibition has advanced to clinical trials in recent years. Consequently, concerns regarding the use of a toxin as a treatment and the search for dose control that does not trigger extreme toxicity have emerged. Thus, it is necessary to investigate alternatives for controlled delivery and targeted toxin administration.
METHODS: This study aimed to evaluate the in vitro toxic action of CTX and its phospholipase A2 CB (PLA2CB) component, both free and encapsulated in polymeric nanoparticles. The inhibitory concentration value of 50% tumor growth (IC50) for CTX and PLA2CB was determined in an initial screening against six tumor cell lines. After identifying the lowest inhibitory concentration value of 0.8 μM observed in human melanoma (SK-MEL-103), this cell line was chosen.
RESULTS: The cell death mechanism triggered by CTX and PLA2CB exhibited characteristics associated with the necrotic process. However, polymeric nanoparticles containing PLA2CB (NP-PLA2CB) demonstrated apoptosis-like cell death processes in flow cytometry. PLGA polymeric nanoparticles containing PLA2CB were synthesized using microfluidics, resulting in NP-PLA2CB with a diameter of 91 ± 2.9 nm and a zeta potential of -21.8 ± 3.2 mV. The encapsulation efficiency of PLA2CB was approximately 70% (protein content).
CONCLUSION: It was concluded that using the phospholipase component of the toxin in a polymeric-controlled delivery and targeted system may be an alternative solution to the issues in advancing this bioactive molecule in clinical-oncological studies. However, further studies are still being conducted for targeted treatment involving this nanotechnological approach.
METHODS: This study aimed to evaluate the in vitro toxic action of CTX and its phospholipase A2 CB (PLA2CB) component, both free and encapsulated in polymeric nanoparticles. The inhibitory concentration value of 50% tumor growth (IC50) for CTX and PLA2CB was determined in an initial screening against six tumor cell lines. After identifying the lowest inhibitory concentration value of 0.8 μM observed in human melanoma (SK-MEL-103), this cell line was chosen.
RESULTS: The cell death mechanism triggered by CTX and PLA2CB exhibited characteristics associated with the necrotic process. However, polymeric nanoparticles containing PLA2CB (NP-PLA2CB) demonstrated apoptosis-like cell death processes in flow cytometry. PLGA polymeric nanoparticles containing PLA2CB were synthesized using microfluidics, resulting in NP-PLA2CB with a diameter of 91 ± 2.9 nm and a zeta potential of -21.8 ± 3.2 mV. The encapsulation efficiency of PLA2CB was approximately 70% (protein content).
CONCLUSION: It was concluded that using the phospholipase component of the toxin in a polymeric-controlled delivery and targeted system may be an alternative solution to the issues in advancing this bioactive molecule in clinical-oncological studies. However, further studies are still being conducted for targeted treatment involving this nanotechnological approach.